<DOC>
	<DOC>NCT00857558</DOC>
	<brief_summary>A multicenter, randomized, double-blind, placebo-controlled, group-comparison study to investigate the safety and efficacy of OPC-262 in patients with type 2 diabetes</brief_summary>
	<brief_title>A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Type 2 diabetes patients with HbA1c above 7.0% and below 10% Patients who are capable of giving informed consent Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner Patients with type1 diabetes mellitus, patients with diabetes mellitus or impaired glucose tolerance (IGT) due to other specified mechanism or diseases, and patients with gestational diabetes mellitus Patients with a medical history of diabetes coma Patients with poorlycontrolled hypertension Patients with heart failure Patients with a complication of active hepatitis or hepatic cirrhosis Patients undergoing treatment of glomeruler diseases other than diabetic nephropathy Patients with a history or complication of malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>